Search for content, post, videos

3 Stocks in the Spotlight with Their Technical: Great Basin Scientific Inc (NASDAQ:GBSN), Stereotaxis (NASDAQ:STXS), Omeros Corporation (NASDAQ:OMER),

Great Basin Scientific Inc (NASDAQ:GBSN), a molecular diagnostics company, reported that the Company has submitted its Staph ID/R Blood Culture Panel to the U.S. Food & Drug Administration for 510(k) clearance. The submission of the Staph ID/R panel, the Company’s first multiplex panel, comes after the successful completion of a clinical trial that met all of Great Basin’s clinical objectives. Great Basin offers the first and only molecular diagnostic platform capable of low-plex tests, as well as multiplex and direct-from-specimen panels. The Great Basin Staph ID/R Blood Culture Panel is a sample-to-result, automated, molecular multiplex panel that detects Staph aureus and two other staph species along with the mecA gene, a major drug resistance marker that confers resistance to methicillin and creates the superbug MRSA. In addition to Staph aureus, the panel also detects Staphylococcus lugdunensis and Staphylococcus epidermidis. The remaining staph species are detected as a group and identified as “Staphylococcus present.” When compared to traditional blood culture methods, results of this panel are expected to allow for a faster diagnosis and therefore a more timely appropriate therapy, which is associated with improved patient outcomes, lower treatment costs, and shorter length of hospital stay for affected patents.

Shares of GBSN plunged -17.10% to end last trade at $ 0.30.

 

Technical Indicators:

  • The current support level is placed at $ 23and the stock is finding resistance at $ 0.37.
  • 80% Barchart technical sell signal
  • Trend Spotter sell signal
  • Moving average direction is bearish as trades above its 20, 50, 200 day SMA
  • Dropped -87.80% so far this year but plunged -89.24% in the past month and is down -71.42% for the week
  • Relative Strength Index (RSI) stands at 11.72

 

Stereotaxis Inc(NASDAQ:STXS), and Westmead Hospital in Australia reported findings of a new study comparing the stability of a Niobe(R) remote magnetic navigation system catheter group and a manually controlled catheter group in a validated cardiac wall motion simulator. Pramesh Kovoor, M.D., Ph.D., Director of Cardiac Services at Westmead Hospital and Associate Professor at the University of Sydney said that The Niobe system has long demonstrated an enhanced safety profile in comparison to conventional ablations, but its efficacy with lesion creation in highly mobile cardiac regions has not been adequately studied. “We were pleasantly surprised with the results of our research, which provided strong evidence of faster, deeper lesion formation utilizing the Niobe system, due to constant catheter contact in the presence of simulated heart wall motion. As a practitioner, this translates into the potential for more precise, effective ablations in unstable regions of the heart, which could lead to improved patient outcomes and shorter procedure times.”

Shares of  STXS plunged -16.67% to end last trade at $ 1.50.

 

Technical Indicators:

  • The current support level is placed at $1.25and the stock is finding resistance at $ 79.
  • 40% Barchart technical but signal
  • Trend Spotter buy signal
  • Moving average direction is bullish as trades above its 20, 50,200 day SMA.
  • Rose 35% so far this year but gained 4.17% in the past month and is up/ down  108.33% for the week
  • Relative Strength Index (RSI) stands at 6 61

 

Omeros Corporation(NASDAQ:OMER), declared additional positive data in the company’s Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies. TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi aggregations of platelets – in the microcirculation of the body’s organs, most commonly the kidney and brain. OMS721 is Omeros’ lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 program for the treatment of TMAs, including atypical hemolytic uremic syndrome.

Shares of OMER plunged -9.10% to end last trade at $ 14.09.

 

Technical Indicators:

  • The current support level is placed at $ 62and the stock is finding resistance at $ 16.12.
  • 80% Barchart technical sell signal
  • Trend Spotter sell signal
  • Moving average direction is bearish as trades above its 20, 50,200 day SMA.
  • Dropped -43.14% so far this year but plunged -12.48% in the past month and is down -21.77% for the week
  • Relative Strength Index (RSI) stands at 41.63